Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

The Challenge of Classifying Metastatic Cell Properties by Molecular Profiling Exemplified with Cutaneous Melanoma Cells and Their Cerebral Metastasis from Patient Derived Mouse Xenografts.

Neuditschko B, Janker L, Niederstaetter L, Brunmair J, Krivanek K, Izraely S, Sagi-Assif O, Meshel T, Keppler BK, Del Favero G, Witz IP, Gerner C.

Mol Cell Proteomics. 2020 Mar;19(3):478-489. doi: 10.1074/mcp.RA119.001886. Epub 2019 Dec 31.

2.

Notch-Mediated Tumor-Stroma-Inflammation Networks Promote Invasive Properties and CXCL8 Expression in Triple-Negative Breast Cancer.

Liubomirski Y, Lerrer S, Meshel T, Morein D, Rubinstein-Achiasaf L, Sprinzak D, Wiemann S, Körner C, Ehrlich M, Ben-Baruch A.

Front Immunol. 2019 Apr 24;10:804. doi: 10.3389/fimmu.2019.00804. eCollection 2019.

3.

Tumor-Stroma-Inflammation Networks Promote Pro-metastatic Chemokines and Aggressiveness Characteristics in Triple-Negative Breast Cancer.

Liubomirski Y, Lerrer S, Meshel T, Rubinstein-Achiasaf L, Morein D, Wiemann S, Körner C, Ben-Baruch A.

Front Immunol. 2019 Apr 12;10:757. doi: 10.3389/fimmu.2019.00757. eCollection 2019.

4.

Regeneration Enhances Metastasis: A Novel Role for Neurovascular Signaling in Promoting Melanoma Brain Metastasis.

Prakash R, Izraely S, Thareja NS, Lee RH, Rappaport M, Kawaguchi R, Sagi-Assif O, Ben-Menachem S, Meshel T, Machnicki M, Ohe S, Hoon DS, Coppola G, Witz IP, Carmichael ST.

Front Neurosci. 2019 Apr 9;13:297. doi: 10.3389/fnins.2019.00297. eCollection 2019.

5.

The metastatic microenvironment: Melanoma-microglia cross-talk promotes the malignant phenotype of melanoma cells.

Izraely S, Ben-Menachem S, Sagi-Assif O, Telerman A, Zubrilov I, Ashkenazi O, Meshel T, Maman S, Orozco JIJ, Salomon MP, Marzese DM, Pasmanik-Chor M, Pikarski E, Ehrlich M, Hoon DSB, Witz IP.

Int J Cancer. 2019 Feb 15;144(4):802-817. doi: 10.1002/ijc.31745. Epub 2018 Nov 1.

6.

Cystatin C takes part in melanoma-microglia cross-talk: possible implications for brain metastasis.

Moshe A, Izraely S, Sagi-Assif O, Prakash R, Telerman A, Meshel T, Carmichael T, Witz IP.

Clin Exp Metastasis. 2018 Aug;35(5-6):369-378. doi: 10.1007/s10585-018-9891-0. Epub 2018 May 2.

7.

ANGPTL4 promotes the progression of cutaneous melanoma to brain metastasis.

Izraely S, Ben-Menachem S, Sagi-Assif O, Meshel T, Marzese DM, Ohe S, Zubrilov I, Pasmanik-Chor M, Hoon DSB, Witz IP.

Oncotarget. 2017 Jul 5;8(44):75778-75796. doi: 10.18632/oncotarget.19018. eCollection 2017 Sep 29.

8.

Co-Inflammatory Roles of TGFβ1 in the Presence of TNFα Drive a Pro-inflammatory Fate in Mesenchymal Stem Cells.

Lerrer S, Liubomirski Y, Bott A, Abnaof K, Oren N, Yousaf A, Körner C, Meshel T, Wiemann S, Ben-Baruch A.

Front Immunol. 2017 May 11;8:479. doi: 10.3389/fimmu.2017.00479. eCollection 2017.

9.

CCR4 is a determinant of melanoma brain metastasis.

Klein A, Sagi-Assif O, Meshel T, Telerman A, Izraely S, Ben-Menachem S, Bayry J, Marzese DM, Ohe S, Hoon DSB, Erez N, Witz IP.

Oncotarget. 2017 May 9;8(19):31079-31091. doi: 10.18632/oncotarget.16076.

10.

Microenvironmental networks promote tumor heterogeneity and enrich for metastatic cancer stem-like cells in Luminal-A breast tumor cells.

Weitzenfeld P, Meshel T, Ben-Baruch A.

Oncotarget. 2016 Dec 6;7(49):81123-81143. doi: 10.18632/oncotarget.13213.

11.

The Beta Subunit of Hemoglobin (HBB2/HBB) Suppresses Neuroblastoma Growth and Metastasis.

Maman S, Sagi-Assif O, Yuan W, Ginat R, Meshel T, Zubrilov I, Keisari Y, Lu W, Lu W, Witz IP.

Cancer Res. 2017 Jan 1;77(1):14-26. doi: 10.1158/0008-5472.CAN-15-2929. Epub 2016 Oct 28.

12.

Hexokinase 2 is a determinant of neuroblastoma metastasis.

Botzer LE, Maman S, Sagi-Assif O, Meshel T, Nevo I, Yron I, Witz IP.

Br J Cancer. 2016 Mar 29;114(7):759-66. doi: 10.1038/bjc.2016.26. Epub 2016 Mar 17.

13.

Chemokine axes in breast cancer: factors of the tumor microenvironment reshape the CCR7-driven metastatic spread of luminal-A breast tumors.

Weitzenfeld P, Kossover O, Körner C, Meshel T, Wiemann S, Seliktar D, Legler DF, Ben-Baruch A.

J Leukoc Biol. 2016 Jun;99(6):1009-25. doi: 10.1189/jlb.3MA0815-373R. Epub 2016 Mar 2.

PMID:
26936935
14.

PHOX2B is a suppressor of neuroblastoma metastasis.

Naftali O, Maman S, Meshel T, Sagi-Assif O, Ginat R, Witz IP.

Oncotarget. 2016 Mar 1;7(9):10627-37. doi: 10.18632/oncotarget.7056.

15.

Regulation of the inflammatory profile of stromal cells in human breast cancer: prominent roles for TNF-α and the NF-κB pathway.

Katanov C, Lerrer S, Liubomirski Y, Leider-Trejo L, Meshel T, Bar J, Feniger-Barish R, Kamer I, Soria-Artzi G, Kahani H, Banerjee D, Ben-Baruch A.

Stem Cell Res Ther. 2015 May 1;6:87. doi: 10.1186/s13287-015-0080-7.

16.

Vemurafenib resistance selects for highly malignant brain and lung-metastasizing melanoma cells.

Zubrilov I, Sagi-Assif O, Izraely S, Meshel T, Ben-Menahem S, Ginat R, Pasmanik-Chor M, Nahmias C, Couraud PO, Hoon DS, Witz IP.

Cancer Lett. 2015 May 28;361(1):86-96. doi: 10.1016/j.canlet.2015.02.041. Epub 2015 Feb 25.

PMID:
25725450
17.

Astrocytes facilitate melanoma brain metastasis via secretion of IL-23.

Klein A, Schwartz H, Sagi-Assif O, Meshel T, Izraely S, Ben Menachem S, Bengaiev R, Ben-Shmuel A, Nahmias C, Couraud PO, Witz IP, Erez N.

J Pathol. 2015 May;236(1):116-27. doi: 10.1002/path.4509. Epub 2015 Feb 12.

PMID:
25639230
18.

Breast cancer: coordinated regulation of CCL2 secretion by intracellular glycosaminoglycans and chemokine motifs.

Lebel-Haziv Y, Meshel T, Soria G, Yeheskel A, Mamon E, Ben-Baruch A.

Neoplasia. 2014 Sep;16(9):723-40. doi: 10.1016/j.neo.2014.08.004.

19.

The metastatic microenvironment: Claudin-1 suppresses the malignant phenotype of melanoma brain metastasis.

Izraely S, Sagi-Assif O, Klein A, Meshel T, Ben-Menachem S, Zaritsky A, Ehrlich M, Prieto VG, Bar-Eli M, Pirker C, Berger W, Nahmias C, Couraud PO, Hoon DS, Witz IP.

Int J Cancer. 2015 Mar 15;136(6):1296-307. doi: 10.1002/ijc.29090. Epub 2014 Sep 8.

20.

The inflammatory cytokine TNFα cooperates with Ras in elevating metastasis and turns WT-Ras to a tumor-promoting entity in MCF-7 cells.

Leibovich-Rivkin T, Liubomirski Y, Meshel T, Abashidze A, Brisker D, Solomon H, Rotter V, Weil M, Ben-Baruch A.

BMC Cancer. 2014 Mar 6;14:158. doi: 10.1186/1471-2407-14-158.

21.
22.

Progression of luminal breast tumors is promoted by ménage à trois between the inflammatory cytokine TNFα and the hormonal and growth-supporting arms of the tumor microenvironment.

Weitzenfeld P, Meron N, Leibovich-Rivkin T, Meshel T, Ben-Baruch A.

Mediators Inflamm. 2013;2013:720536. doi: 10.1155/2013/720536. Epub 2013 Dec 4.

23.

The metastatic microenvironment: lung-derived factors control the viability of neuroblastoma lung metastasis.

Maman S, Edry-Botzer L, Sagi-Assif O, Meshel T, Yuan W, Lu W, Witz IP.

Int J Cancer. 2013 Nov 15;133(10):2296-306. doi: 10.1002/ijc.28255. Epub 2013 Jun 14.

24.

The metastatic microenvironment: Brain-derived soluble factors alter the malignant phenotype of cutaneous and brain-metastasizing melanoma cells.

Klein A, Sagi-Assif O, Izraely S, Meshel T, Pasmanik-Chor M, Nahmias C, Couraud PO, Erez N, Hoon DS, Witz IP.

Int J Cancer. 2012 Dec 1;131(11):2509-18. doi: 10.1002/ijc.27552. Epub 2012 Apr 12.

25.

Mechanisms regulating the secretion of the promalignancy chemokine CCL5 by breast tumor cells: CCL5's 40s loop and intracellular glycosaminoglycans.

Soria G, Lebel-Haziv Y, Ehrlich M, Meshel T, Suez A, Avezov E, Rozenberg P, Ben-Baruch A.

Neoplasia. 2012 Jan;14(1):1-19.

26.

Tumor-promoting circuits that regulate a cancer-related chemokine cluster: dominance of inflammatory mediators over oncogenic alterations.

Leibovich-Rivkin T, Buganim Y, Solomon H, Meshel T, Rotter V, Ben-Baruch A.

Cancers (Basel). 2012 Jan 20;4(1):55-76. doi: 10.3390/cancers4010055.

27.

Transendothelial migration of lymphocytes mediated by intraendothelial vesicle stores rather than by extracellular chemokine depots.

Shulman Z, Cohen SJ, Roediger B, Kalchenko V, Jain R, Grabovsky V, Klein E, Shinder V, Stoler-Barak L, Feigelson SW, Meshel T, Nurmi SM, Goldstein I, Hartley O, Gahmberg CG, Etzioni A, Weninger W, Ben-Baruch A, Alon R.

Nat Immunol. 2011 Dec 4;13(1):67-76. doi: 10.1038/ni.2173.

PMID:
22138716
28.

The metastatic microenvironment: brain-residing melanoma metastasis and dormant micrometastasis.

Izraely S, Sagi-Assif O, Klein A, Meshel T, Tsarfaty G, Pasmanik-Chor M, Nahmias C, Couraud PO, Ateh E, Bryant JL, Hoon DS, Witz IP.

Int J Cancer. 2012 Sep 1;131(5):1071-82. doi: 10.1002/ijc.27324. Epub 2011 Dec 2.

29.

Lung-residing metastatic and dormant neuroblastoma cells.

Edry Botzer L, Maman S, Sagi-Assif O, Meshel T, Nevo I, Bäuerle T, Yron I, Witz IP.

Am J Pathol. 2011 Jul;179(1):524-36. doi: 10.1016/j.ajpath.2011.03.020. Epub 2011 May 3.

30.

Inflammatory mediators in breast cancer: coordinated expression of TNFα & IL-1β with CCL2 & CCL5 and effects on epithelial-to-mesenchymal transition.

Soria G, Ofri-Shahak M, Haas I, Yaal-Hahoshen N, Leider-Trejo L, Leibovich-Rivkin T, Weitzenfeld P, Meshel T, Shabtai E, Gutman M, Ben-Baruch A.

BMC Cancer. 2011 Apr 12;11:130. doi: 10.1186/1471-2407-11-130.

32.

Chemokine-chemokine receptor axes in melanoma brain metastasis.

Izraely S, Klein A, Sagi-Assif O, Meshel T, Tsarfaty G, Hoon DS, Witz IP.

Immunol Lett. 2010 May 4;130(1-2):107-14. doi: 10.1016/j.imlet.2009.12.003. Epub 2009 Dec 30.

PMID:
20005902
33.

Reduced expression of chemoattractant receptors by polymorphonuclear leukocytes in Hyper IgE Syndrome patients.

Mintz R, Garty BZ, Meshel T, Marcus N, Katanov C, Cohen-Hillel E, Ben-Baruch A.

Immunol Lett. 2010 May 4;130(1-2):97-106. doi: 10.1016/j.imlet.2009.12.006. Epub 2009 Dec 11.

PMID:
20005258
34.

Chemokines in human breast tumor cells: modifying their expression levels and determining their effects on the malignancy phenotype.

Soria G, Meshel T, Ben-Baruch A.

Methods Enzymol. 2009;460:3-16. doi: 10.1016/S0076-6879(09)05201-X.

PMID:
19446718
35.

Cell migration to the chemokine CXCL8: paxillin is activated and regulates adhesion and cell motility.

Cohen-Hillel E, Mintz R, Meshel T, Garty BZ, Ben-Baruch A.

Cell Mol Life Sci. 2009 Mar;66(5):884-99. doi: 10.1007/s00018-009-8447-5.

PMID:
19151925
36.

Concomitant expression of the chemokines RANTES and MCP-1 in human breast cancer: a basis for tumor-promoting interactions.

Soria G, Yaal-Hahoshen N, Azenshtein E, Shina S, Leider-Trejo L, Ryvo L, Cohen-Hillel E, Shtabsky A, Ehrlich M, Meshel T, Keydar I, Ben-Baruch A.

Cytokine. 2008 Oct;44(1):191-200. doi: 10.1016/j.cyto.2008.08.002. Epub 2008 Sep 13.

PMID:
18790652
37.

The involvement of the fractalkine receptor in the transmigration of neuroblastoma cells through bone-marrow endothelial cells.

Nevo I, Sagi-Assif O, Meshel T, Ben-Baruch A, Jöhrer K, Greil R, Trejo LE, Kharenko O, Feinmesser M, Yron I, Witz IP.

Cancer Lett. 2009 Jan 8;273(1):127-39. doi: 10.1016/j.canlet.2008.07.029. Epub 2008 Sep 7.

PMID:
18778890
38.

The involvement of the sLe-a selectin ligand in the extravasation of human colorectal carcinoma cells.

Ben-David T, Sagi-Assif O, Meshel T, Lifshitz V, Yron I, Witz IP.

Immunol Lett. 2008 Mar 15;116(2):218-24. doi: 10.1016/j.imlet.2007.11.022. Epub 2007 Dec 26.

PMID:
18191232
39.

Intracellular cross-talk between the GPCR CXCR1 and CXCR2: role of carboxyl terminus phosphorylation sites.

Attal H, Cohen-Hillel E, Meshel T, Wang JM, Gong W, Ben-Baruch A.

Exp Cell Res. 2008 Jan 15;314(2):352-65. Epub 2007 Sep 29.

PMID:
17996233
40.
41.

CXCL10 promotes invasion-related properties in human colorectal carcinoma cells.

Zipin-Roitman A, Meshel T, Sagi-Assif O, Shalmon B, Avivi C, Pfeffer RM, Witz IP, Ben-Baruch A.

Cancer Res. 2007 Apr 1;67(7):3396-405.

42.

CXCL8-induced FAK phosphorylation via CXCR1 and CXCR2: cytoskeleton- and integrin-related mechanisms converge with FAK regulatory pathways in a receptor-specific manner.

Cohen-Hillel E, Yron I, Meshel T, Soria G, Attal H, Ben-Baruch A.

Cytokine. 2006 Jan 7;33(1):1-16. Epub 2006 Jan 9.

PMID:
16406804
43.

Cellular characteristics of neuroblastoma cells: regulation by the ELR--CXC chemokine CXCL10 and expression of a CXCR3-like receptor.

Goldberg-Bittman L, Sagi-Assif O, Meshel T, Nevo I, Levy-Nissenbaum O, Yron I, Witz IP, Ben-Baruch A.

Cytokine. 2005 Feb 7;29(3):105-17. Epub 2004 Dec 2.

PMID:
15613278
44.

The angiogenic factors CXCL8 and VEGF in breast cancer: regulation by an array of pro-malignancy factors.

Azenshtein E, Meshel T, Shina S, Barak N, Keydar I, Ben-Baruch A.

Cancer Lett. 2005 Jan 10;217(1):73-86.

PMID:
15596298
45.

Tumor-microenvironment interactions: the fucose-generating FX enzyme controls adhesive properties of colorectal cancer cells.

Zipin A, Israeli-Amit M, Meshel T, Sagi-Assif O, Yron I, Lifshitz V, Bacharach E, Smorodinsky NI, Many A, Czernilofsky PA, Morton DL, Witz IP.

Cancer Res. 2004 Sep 15;64(18):6571-8. Erratum in: Cancer Res. 2004 Nov 1;64(21):8130.

46.

The expression of the chemokine receptor CXCR3 and its ligand, CXCL10, in human breast adenocarcinoma cell lines.

Goldberg-Bittman L, Neumark E, Sagi-Assif O, Azenshtein E, Meshel T, Witz IP, Ben-Baruch A.

Immunol Lett. 2004 Mar 29;92(1-2):171-8.

PMID:
15081542
47.

The tumor microenvironment: CXCR4 is associated with distinct protein expression patterns in neuroblastoma cells.

Nevo I, Sagi-Assif O, Meshel T, Geminder H, Goldberg-Bittman L, Ben-Menachem S, Shalmon B, Goldberg I, Ben-Baruch A, Witz IP.

Immunol Lett. 2004 Mar 29;92(1-2):163-9.

PMID:
15081541
48.

IL-8-induced migratory responses through CXCR1 and CXCR2: association with phosphorylation and cellular redistribution of focal adhesion kinase.

Feniger-Barish R, Yron I, Meshel T, Matityahu E, Ben-Baruch A.

Biochemistry. 2003 Mar 18;42(10):2874-86.

PMID:
12627953
49.

Intracellular trafficking of human CXCR1 and CXCR2: regulation by receptor domains and actin-related kinases.

Matityahu E, Feniger-Barish R, Meshel T, Zaslaver A, Ben-Baruch A.

Eur J Immunol. 2002 Dec;32(12):3525-35.

50.

A possible role for CXCR4 and its ligand, the CXC chemokine stromal cell-derived factor-1, in the development of bone marrow metastases in neuroblastoma.

Geminder H, Sagi-Assif O, Goldberg L, Meshel T, Rechavi G, Witz IP, Ben-Baruch A.

J Immunol. 2001 Oct 15;167(8):4747-57.

Supplemental Content

Loading ...
Support Center